English cross-cultural translation and validation of the NM-Score: a system for motor function classification in patients with neuromuscular diseases
Vuillerot C, Meilleur KG, Jain M, Waite M, Wu T, Linton M, Datsgir J, Donkervoort S, Leach ME, Rutkowski A, Rippert P, Payan C, Iwaz J, Hamroun D, Bérard C, Poirot I, Bönnemann CG.
Arch Phys Med Rehabil. 2014. 95(11):2064-2070.e1.
Developement of an English version of the NM-Score. Its concurrent validity was tested in 42 patients aged 5 to 19 years old with a confirmed or suspected diagnosis of congenital muscular dystrophy against criterion standards (Brooke, MFM, Activlim, Jebsen Test, and myometry). Informant agreements between patient-reported and clinician-reported NM-Score were measured by weighted Kappa. Significant correlation coefficients were found between NM-Score and criterion standards MFM D1, Activlim and Hip abduction. Informant agreements between clinician- and patient-reported NM scores were excellent for D1 but moderate for D2 and D3. The English version is thus a reliable and valid instrument that can be used in clinical practice and research to describe the functional abilities of patients with neuromuscular diseases.
Keywords: Neuromuscular diseases, activities of daily living, disability evaluation, rehabilitation
Articles dans les revues scientifiques
Assessment of disease progression in dysferlinopathy: A 1-year cohort study
Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M,...
Disease duration and disability in dysfelinopathy can be described by muscle imaging using heatmaps and random forests.
Gómez-Andrés D, Díaz J, Munell F, Sánchez-Montáñez Á, Pulido-Valdeolivas I, Suazo L, Garrido C, Quijano-Roy S, Bevilacqua JA. Muscle Nerve. 2019. 59(4), 436-444. The manner in which imaging patterns change over the disease course and with increasing disability in...
Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?
Witherspoon JW, Vasavada R, Logaraj RH, Waite M, Collins J, Shieh C, Meilleur K, Bönnemann C, Jain M. Eur J Paediatr Neurol. 2019. 23 (1), 165-170. The primary objective of this study is to establish the utility of the 2-min walk test (2MWT) in patients with...
Correlation of phenotype with genotype and protein structure in RYR1-related disorders
Todd JJ, Sagar V, Lawal TA, Allen C, Razaqyar MS, Shelton MS, Chrismer IC, Zhang X, Cosgrove MM, Kuo A, Vasavada R, Jain MS, Waite M, Rajapakse D, Witherspoon JW, Wistow G, Meilleur KG. J Neurol. 2018. 265(11), 2506-2524. Variants in the skeletal muscle ryanodine...
Nusinersen in spinal muscular atrophy type 1 patients older than 7 months: A cohort study
Aragon-Gawinska K, Seferian AM, Daron A, Gargaun E, Vuillerot C, Cances C, Ropars J, Chouchane M, Cuppen I, Hughes I, Illingworth M, Marini-Bettolo C, Rambaud J, Taytard J, Annoussamy M, Scoto M, Gidaro T, Servais L. Neurology. 2018. 91(14), e1312-e1318. The study...
Functional assessment tools in children with Pompe disease: A pilot comparative study to identify suitable outcome measures for the standard of care
Ricci F, Brusa C, Rossi F, Rolle E, Placentino V, Berardinelli A, Pagliardini V, Porta F, Spada M, Mongini T. Eur J Paediatr Neurol 2018. 22(6),1103-1109. Progression of Pompe disease was evaluated in 8 young patients. From the results of the study, the authors...